In addition to leukemia, MAP2K7 inhibition may also benefit cancers associated with increased activation of the MAP2K7-JNK pathway, such as liver metastasis of colon cancer, glioblastoma, and prostate cancer. This evidence concerns the gene MAP2K7 and cancer.